Valmont Industries (NYSE:VMI) -12% in Friday's trading to a five-month low after William Blair downgrades the infrastructure company to Market Perform from Outperform, citing potential for significant ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Truist Financial analyst Keith Hughes maintained a Hold rating on Beacon Roofing Supply (BECN – Research Report) today. The company’s shares ...

As Klarna wins installment lending for the retail giant's OnePay app, rival Affirm seeks to downplay the loss.

Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps ...

Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, March 18th.

Fintel reports that on March 20, 2025, William Blair downgraded their outlook for Beacon Roofing Supply (NasdaqGS:BECN) from ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Emerging markets present a landscape of opportunity for equity investors despite macroeconomic headwinds. Click to read.

So while NCAA Tournament teams began preparing for their first-round opponents on Sunday night, Texas won't know who it is ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Overall, Palantir has had a solid start to 2025. Its growth numbers look impressive, and its AI platform is gaining traction across industries. Yet not everyone is convinced. Some ...